10x Science
AI-powered platform helping pharmaceutical researchers understand complex molecules for drug discovery
10xscience.com ↗📍 San Francisco, California
Verified Data
“Based on $4.8M seed funding, 3-person team, and early-stage status with private beta customers. Typical early-stage B2B SaaS companies post-seed generate $100K-$500K ARR.”
“monthly_web_traffic_similarweb: < 5,000 (Estimate, platform is recently launched)”
“user_customer_count: Private beta / Partner-based”
“Expanding engineering team and deepening biopharma collaborations following $4.8M seed round (April 2026)”
Company Profile
Contact
Strategic Analysis
Strategy
Building AI-native protein characterization platform to solve the drug discovery bottleneck by helping pharma companies understand complex molecules at the molecular level. Targeting the gap between AI-generated drug candidates and determining which ones actually matter for development.
Tactics
Operating in private beta with pharmaceutical and biotech partners to validate platform. Expanding engineering team post-seed funding to scale AI capabilities. Leveraging Y Combinator network and Initialized Capital backing for biopharma industry connections.
Competitive Positioning
Positioned as solving the bottleneck in AI-driven drug discovery where companies can generate potential drugs but struggle to characterize and validate them. Differentiates on molecular-level protein understanding versus broader drug discovery platforms.
Marketing Approach
Partner-based go-to-market strategy working directly with pharmaceutical and biotech companies. Leveraging industry relationships and Y Combinator network for customer acquisition rather than traditional marketing channels.
Notable
Y Combinator W26 batch, oversubscribed seed round led by Initialized Capital
🔗 Source ↗Tech Stack
Python
PyTorch
CloudflareGoogle WorkspaceMicrosoft Office 365Recent News
Related AI Healthcare Companies
Discovery Sources
Signals
“monthly_web_traffic_similarweb: < 5,000 (Estimate, platform is recently launched)”
“Expanding engineering team and deepening biopharma collaborations following $4.8M seed round (April 2026)”
“user_customer_count: Private beta / Partner-based”
Evidence
10x Science has raised a $4.8 million seed round to help pharmaceutical researchers understand complex molecules.
$4.8M seed from Initialized Capital
3 employees